Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628126 | 1.00 | SCN8A (1.00) | SCN8ASCN1A | |
| Formic Acid SCHEMBL21772995 | 0.96 | SCN8A (0.92) | SCN8ASCN1A | |
| Formic Acid SCHEMBL28549350 | 0.96 | SCN8A (0.92) | SCN8ASCN1A | |
| SCHEMBL21773144 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL21773148 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613021 | 0.86 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613024 | 0.86 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613375 | 0.84 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613377 | 0.84 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612989 | 0.84 | SCN8A (1.00) | SCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638898-A | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2021-04-09 | — | — | CN | claimed |
| US-12558326-B2 | Method for treating epilepsy | XENON PHARMACEUTICALS INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20240408075-A1 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2024-12-12 | — | — | US | disclosed |
| EP-3829558-B1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC (CA) | 2024-07-03 | — | — | EP | disclosed |
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4291185-A1 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | Xenon Pharmaceuticals Inc. (CA) | 2023-12-20 | — | — | EP | disclosed |
| CN-117015379-A | Combination therapy for the treatment of seizure disorders | 泽农医药公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3829558-A1 | METHOD FOR TREATING EPILEPSY | Xenon Pharmaceuticals Inc. (CA) | 2021-06-09 | — | — | EP | disclosed |
| CN-112930175-A | Method for treating epilepsy | 泽农医药公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-112638898-A | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2021-04-09 | — | — | CN | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| WO-2020023923-A1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC. (CA) | 2020-01-30 | — | — | WO | disclosed |
| US-20200030260-A1 | METHOD FOR TREATING EPILEPSY | XENON PHARMACEUTICALS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885 |
| US-20200030260-A1 | METHOD FOR TREATING EPILEPSY | PNMT, HTR5A, TPH1 | SCN8A 323/4885SCN1A 132/4885 |
| US-20240408075-A1 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | SMPD4, PNMT, NPY4R | SCN8A 48/4885SCN1A 153/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885 |
| US-12558326-B2 | Method for treating epilepsy | PNMT, SLC6A1, CPT1B | SCN8A 247/4885SCN1A 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.